Intracardiac thrombus in children with dilated cardiomyopathy

Objectives: The risk of fatal pulmonary and systemic thromboembolism is high in patients with dilated cardiomyopathy with cardiac thrombus. This study was planned to reveal the efficacy of antiaggregant therapy in patients with low left ventricular systolic ejection fraction (LVEF). Study design:...

Full description

Bibliographic Details
Main Authors: Ahmet İrdem, Osman Başpınar, Mehmet Kervancıoğlu, Metin Kılınç
Format: Article
Language:English
Published: KARE Publishing 2014-02-01
Series:Türk Kardiyoloji Derneği Arşivi
Subjects:
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-81593
_version_ 1828028810952441856
author Ahmet İrdem
Osman Başpınar
Mehmet Kervancıoğlu
Metin Kılınç
author_facet Ahmet İrdem
Osman Başpınar
Mehmet Kervancıoğlu
Metin Kılınç
author_sort Ahmet İrdem
collection DOAJ
description Objectives: The risk of fatal pulmonary and systemic thromboembolism is high in patients with dilated cardiomyopathy with cardiac thrombus. This study was planned to reveal the efficacy of antiaggregant therapy in patients with low left ventricular systolic ejection fraction (LVEF). Study design: The present study retrospectively reviewed the files of 83 cases (42 males, 41 females) with dilated cardiomyopathy who were followed between June 2004 and December 2011. Results: Intracardiac thrombus was detected in five (6%) cases; of these five patients, dilated cardiomyopathy was idiopathic in four and secondary to chronic renal failure in one. The cases were followed for a mean of 33.6+-35.6 months (3 days-168 months). Mean LVEF on transthoracic echocardiography was found as 35.2+-2.7% (32-38%) for the cases with intracardiac thrombus, whereas it was 34.7+-11.0% (10-55%) for the cases without intracardiac thrombus. No statistically significant difference was found between the groups (p=0.910). Cases with LVEF ≤30% were routinely receiving acetylsalicylic acid at antiaggregant dose. Conclusion: We think that prophylactic antithrombotic/antiaggregant therapy should be started at the time of diagnosis even in patients with LVEF >30%, as thrombus development was seen in cases with LVEF >30% without any antiaggregant therapy.
first_indexed 2024-04-10T13:59:41Z
format Article
id doaj.art-1ece089447014ebc81e0f0ae37c89fb5
institution Directory Open Access Journal
issn 1016-5169
language English
last_indexed 2024-04-10T13:59:41Z
publishDate 2014-02-01
publisher KARE Publishing
record_format Article
series Türk Kardiyoloji Derneği Arşivi
spelling doaj.art-1ece089447014ebc81e0f0ae37c89fb52023-02-15T16:10:19ZengKARE PublishingTürk Kardiyoloji Derneği Arşivi1016-51692014-02-0142216116710.5543/tkda.2014.81593TKDA-81593Intracardiac thrombus in children with dilated cardiomyopathyAhmet İrdem0Osman Başpınar1Mehmet Kervancıoğlu2Metin Kılınç3Department of Pediatric Cardiology, Gaziantep University Faculty of Medicine, GaziantepDepartment of Pediatric Cardiology, Gaziantep University Faculty of Medicine, GaziantepDepartment of Pediatric Cardiology, Gaziantep University Faculty of Medicine, GaziantepDepartment of Pediatric Cardiology, Gaziantep University Faculty of Medicine, GaziantepObjectives: The risk of fatal pulmonary and systemic thromboembolism is high in patients with dilated cardiomyopathy with cardiac thrombus. This study was planned to reveal the efficacy of antiaggregant therapy in patients with low left ventricular systolic ejection fraction (LVEF). Study design: The present study retrospectively reviewed the files of 83 cases (42 males, 41 females) with dilated cardiomyopathy who were followed between June 2004 and December 2011. Results: Intracardiac thrombus was detected in five (6%) cases; of these five patients, dilated cardiomyopathy was idiopathic in four and secondary to chronic renal failure in one. The cases were followed for a mean of 33.6+-35.6 months (3 days-168 months). Mean LVEF on transthoracic echocardiography was found as 35.2+-2.7% (32-38%) for the cases with intracardiac thrombus, whereas it was 34.7+-11.0% (10-55%) for the cases without intracardiac thrombus. No statistically significant difference was found between the groups (p=0.910). Cases with LVEF ≤30% were routinely receiving acetylsalicylic acid at antiaggregant dose. Conclusion: We think that prophylactic antithrombotic/antiaggregant therapy should be started at the time of diagnosis even in patients with LVEF >30%, as thrombus development was seen in cases with LVEF >30% without any antiaggregant therapy.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-81593cardiomyopathydilated/complicationschild; coronary thrombosis; thrombectomy; ventricular dysfunctionleft/complications.
spellingShingle Ahmet İrdem
Osman Başpınar
Mehmet Kervancıoğlu
Metin Kılınç
Intracardiac thrombus in children with dilated cardiomyopathy
Türk Kardiyoloji Derneği Arşivi
cardiomyopathy
dilated/complications
child; coronary thrombosis; thrombectomy; ventricular dysfunction
left/complications.
title Intracardiac thrombus in children with dilated cardiomyopathy
title_full Intracardiac thrombus in children with dilated cardiomyopathy
title_fullStr Intracardiac thrombus in children with dilated cardiomyopathy
title_full_unstemmed Intracardiac thrombus in children with dilated cardiomyopathy
title_short Intracardiac thrombus in children with dilated cardiomyopathy
title_sort intracardiac thrombus in children with dilated cardiomyopathy
topic cardiomyopathy
dilated/complications
child; coronary thrombosis; thrombectomy; ventricular dysfunction
left/complications.
url https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-81593
work_keys_str_mv AT ahmetirdem intracardiacthrombusinchildrenwithdilatedcardiomyopathy
AT osmanbaspınar intracardiacthrombusinchildrenwithdilatedcardiomyopathy
AT mehmetkervancıoglu intracardiacthrombusinchildrenwithdilatedcardiomyopathy
AT metinkılınc intracardiacthrombusinchildrenwithdilatedcardiomyopathy